Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2026)

Vir Biotechnology has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $170000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $170000.0, up 102.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.9 million (up 305.07% YoY), and the FY2025 annual result was $7.3 million, up 32.58% from the prior year.
• Gains from Investment Securities came in at $170000.0 for Q1 2026 at Vir Biotechnology, down from $11.7 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $119.9 million in Q3 2022 to a low of -$20.9 million in Q4 2023.
• The 5-year median for Gains from Investment Securities is $117000.0 (2022), against an average of $7.8 million.
• Peak annual rise in Gains from Investment Securities reached 20373.44% in 2023, while the deepest fall reached 21715.0% in 2023.
• Vir Biotechnology's Gains from Investment Securities stood at -$8.9 million in 2022, then plunged by 135.33% to -$20.9 million in 2023, then jumped by 126.46% to $5.5 million in 2024, then jumped by 111.0% to $11.7 million in 2025, then sank by 98.54% to $170000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $170000.0 (Q1 2026), $11.7 million (Q4 2025), and -$11.9 million (Q3 2025), per Business Quant data.